To reconcile the known osteolysis-inhibiting effects of systemically administered osteoprotegerin [8], and osteolysis-inducing effects of OPG locally produced by metastasizing cancer cells [12], we extend the model to account for OPG produced locally by cancer cells. This evidence concerns the gene TNFRSF11B and cancer.